

Investigation Report on China Adefovir Market, 2010-2019

<https://marketpublishers.com/r/IB12E1FB7B9EN.html>

Date: July 2015

Pages: 35

Price: US\$ 2,000.00 (Single User License)

ID: IB12E1FB7B9EN

Abstracts

Description

In Mar. 2015, WHO issued Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection, indicating that 2 billion people around the world had or are having HBV infection and that about 240 million people are infected with chronic hepatitis B virus (HBV), among which 0.65 million die of hepatitis B-related diseases. Hepatitis B surface antigen (HBsAg) rate among people aged below 60 has fallen from 9.75% a decade ago to 7.18% now. However, since China has a large population base, the number of people infected with chronic HBV is calculated to be over 90 million and the number of chronic hepatitis B (CHB) patients is 20 million. Hence, the severe status of diagnosis and treatment of CHB. So far, chronic and viral hepatitis B has become one of the major threats to human health and CHB has already become the ninth leading cause of death.

Nucleotide analog, the leading antiviral product for the treatment of CHB, has such main varieties as entecavir, adefovir dipivoxil, lamivudine, telbivudine, emtricitabine and tenofovir disoproxil in the clinic.

In 2002, GlaxoSmithKline (GSK) acquired the franchise rights to market adefovir dipivoxil, the anti-hepatitis B drug of Gilead Sciences, Inc. in mainland China, Japan, Korea and Taiwan under the trade name of Hepsera. In 2013, the global sales value of Hepsera was down by 23.81%. In 2005, adefovir dipivoxil made by GSK was first approved to enter China under the trade name of Hepsera.

Adefovir develops fast after entering China, annual sales value rising from about CNY 10 million in 2005 to CNY 400 million in 2013 and CAGR reaching nearly 60% during

the period of 2005-2014. GlaxoSmithKline (Tianjin) Co., Ltd, United Laboratories, Fujian Cosunter Pharmaceutical Co., Ltd and Chia Tai Tianqing Pharmaceutical Group Co., Ltd occupy the majority of the Chinese market, among which GlaxoSmithKline (Tianjin) Co., Ltd had the largest market share of about 43% for sales value in 2014.

With the large amounts of hepatitis B patients in China, the market size of adefovir is expected to keep growing in the next few years.

Readers can get at least the following information from this report:

- market size of adefovir in China

- competitive landscape of adefovir in Chinese market

- price of adefovir made by different enterprises in China

- market outlook of adefovir in China

The author suggests the following groups of people purchase this report:

- manufacturers of anti-hepatitis drugs

- investors/ research institutions interested in Chinese medicine market

- any interest in the Chinese medicine market, please contact CRI for customized survey service

Contents

1 RELATED CONCEPTS OF ADEFOVIR

- 1.1 Indication
- 1.2 Sales Status in Global Market

2 MARKET PROFILE OF ADEFOVIR IN CHINA

- 2.1 Patent and Approval Status of Adefovir in China
- 2.2 Major Manufacturers
- 2.3 Market Size

3 SURVEY ON SALES STATUS OF ADEFOVIR IN CHINA, 2010-2014

- 3.1 Sales Value
 - 3.1.1 Overall Sales Value
 - 3.1.2 Sales Value by Regions
- 3.2 Sales Volume
 - 3.2.1 Overall Sales Volume
 - 3.2.2 Sales Volume by Regions

4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF ADEFOVIR IN CHINA, 2010-2014

- 4.1 Market Share by Sales Value
- 4.2 Market Share by Sales Volume

5 SURVEY ON DOSAGE FORMS OF ADEFOVIR IN CHINA, 2010-2014

- 5.1 Share of Different Dosage Forms by Sales Value
- 5.2 Share of Different Dosage Forms by Sales Volume

6 REFERENCE PRICE OF ADEFOVIR IN CHINESE HOSPITALS IN 2014

- 6.1 YSY (Shanghai) Pharmaceutical Co., Ltd
- 6.2 TIPR Pharmaceutical Responsible Co., Ltd (Trade Name: Daiding)
- 6.3 Qilu Pharmaceutical Co., Ltd (Trade Name: Yilaifen)
- 6.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Mingzheng)

6.5 United Laboratories (Trade Name: Adixian)

6.6 Fujian Cosunter Pharmaceutical Co., Ltd (Trade Name: Aganding)

6.7 GlaxoSmithKline (Tianjin) Co., Ltd (Trade Name: Hepsera)

7 MAJOR MANUFACTURERS OF ADEFOVIR IN CHINESE MARKET, 2010-2014

7.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd

7.2 TIPR Pharmaceutical Responsible Co., Ltd

7.3 United Laboratories

7.4 Fujian Cosunter Pharmaceutical Co., Ltd

7.5 GlaxoSmithKline (Tianjin) Co., Ltd

8 MARKET OUTLOOK OF ADEFOVIR IN CHINA, 2015-2019

8.1 Forecast of Market Size

8.2 Forecast of Competitive Landscape

TABLE OF SELECTED CHARTS

Chart Patent Status of Adefovir in China

Chart Approval Information of Adefovir in China

Chart Sales Status of Adefovir in China

Chart Sales Value of Adefovir in China, 2010-2014

Chart Sales Value of Adefovir in Some Regions in China, 2010-2014

Chart Sales Volume of Adefovir in China, 2010-2014

Chart Market Share of TOP3 Manufacturers of Adefovir for Sales Value in China, 2010-2014

Chart Sales Value and Market Share of Adefovir Made by GlaxoSmithKline (Tianjin) in China, 2010-2014

Chart Sales Value and Market Share of Adefovir Made by Chia Tai Tianqing in China, 2010-2014

Chart Sales Value and Market Share of Adefovir Made by TIPR in China, 2010-2014

Chart Sales Value and Market Share of Adefovir Tablets in China, 2010-2014

Chart Sales Value and Market Share of Adefovir Capsules in China, 2010-2014

Chart Price of Adefovir Made by YSY (Shanghai) Pharmaceutical Co., Ltd in Some Chinese Cities in 2014

Chart Price of Adefovir Made by TIPR Pharmaceutical Responsible Co., Ltd in Some Chinese Cities in 2014

Chart Price of Adefovir Made by Qilu Pharmaceutical Co., Ltd in Some Chinese Cities in

2014

Chart Price of Adefovir Made by Chia Tai Tianqing Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014

Chart Price of Adefovir Made by United Laboratories in Some Chinese Cities in 2014

Chart Price of Adefovir Made by Fujian Cosunter Pharmaceutical Co., Ltd in Some Chinese Cities in 2014

Chart Price of Adefovir Made by GlaxoSmithKline (Tianjin) Co., Ltd in Some Chinese Cities in 2014

I would like to order

Product name: Investigation Report on China Adefovir Market, 2010-2019

Product link: <https://marketpublishers.com/r/IB12E1FB7B9EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IB12E1FB7B9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970